A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Triple Negative Breast Cancer
Interventions: DRUG: Carelizumab|DRUG: Nab-paclitaxel|DRUG: Apatinib
Sponsor: Jiangsu HengRui Medicine Co., Ltd.